Forward-Looking Statements
Certain statements in this slide presentation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of these statements relate to estimated future revenue, gross margins and earnings per share, and the continuing impact from the results of the AiMI trial. These statements are based on our current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements such as the effectiveness of our sales and marketing efforts in re-establishing coronary product usage, our ability to effectively manage new product development timelines and our ability to generate suitable clinical registry data to support growing use of the AngioJet System in coronary applications. A discussion of these and other factors that could impact the Company’s future results are set forth in the cautionary statements included in Exhibit 99 to the Company’s Form 10K for the year ended July 31, 2004, filed with the Securities and Exchange Commission.